Almaghrabi, F. ., Nwaru, B. I., Sheikh, A. ., Tsanas, A. ., Tibble, H. ., Critchley, H. ., … Shah, S. A. (2025). Exogenous sex steroid hormones and asthma phenotypes: a study protocol for a prospective cohort analysis with UK-wide primary care data. BMJ Open, 15, e097126. http://doi.org/10.1136/bmjopen-2024-097126
Observational study
Lewis, G. A., Hughes, D. M., Irving, G. ., Wilding, J. ., & Hardy, K. . (2025). Association between diabetes self-management education attendance, hospital admissions and mortality in type 2 diabetes: A cohort analysis protocol. Diabetes Obes Metab. http://doi.org/10.1111/dom.16257
Bottle, A. ., Adamson, A. ., Zhang, X. ., Hayhoe, B. ., & J, Q. . (2024). What happens between first symptoms and first acute exacerbation of COPD - observational study of routine data and patient survey. Health Soc Care Deliv Res, 12, 1–80. http://doi.org/10.3310/cgtr6370
Stimson, J. ., McKeever, T. M., Agnew, E. ., Lim, W. S., Royal, S. ., Myles, P. ., … Robotham, J. V. (2024). Risk of unintended consequences from lower antibiotic prescribing for respiratory tract infections in primary care. J Infect, 89, 106255. http://doi.org/10.1016/j.jinf.2024.106255
Lalmohamed, A. ., Venekamp, R. P., Bolhuis, A. ., Souverein, P. C., van de Wijgert, J. ., Gulliford, M. C., & Hay, A. D. (2024). Within-episode repeat antibiotic prescriptions in patients with respiratory tract infections: A population-based cohort study. J Infect, 88, 106135. http://doi.org/10.1016/j.jinf.2024.106135
Davies, M. J., Alibegovic, A. C., Kelkar, P. ., Braae, U. C., & Jensen, A. B. (2023). Glycaemic control and weight outcomes after adding or switching to biphasic insulin aspart 30/70 in people with type 2 diabetes mellitus previously treated with basal-bolus insulin in UK clinical practice. Diabetes Obes Metab. http://doi.org/10.1111/dom.15278
Alkabbani, W. ., Shah, B. R., Zongo, A. ., Eurich, D. T., Alsabbagh, M. W., & Gamble, J. M. (2023). Post-initiation predictors of discontinuation of the sodium-glucose cotransporter-2 inhibitors: A comparative cohort study from the United Kingdom. Diabetes Obes Metab. http://doi.org/10.1111/dom.15241
von Arx, L. B., Rachman, J. ., Webb, J. ., Casey, C. ., Patel, A. ., Diomatari, C. ., … Idris, I. . (2023). Therapeutic inertia related to the injectable glucagon-like peptide-1 receptor agonists dulaglutide and semaglutide in patients with type 2 diabetes in UK primary care. Diabetes Obes Metab. http://doi.org/10.1111/dom.14985
Birkeland, K. I., Bodegard, J. ., Banerjee, A. ., Kim, D. J., Norhammar, A. ., Eriksson, J. W., … Kadowaki, T. . (2021). Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study. Diabetes Obes Metab, 23, 75–85. http://doi.org/10.1111/dom.14189
Idris, I. ., Zhang, R. ., Mamza, J. B., Ford, M. ., Morris, T. ., Banerjee, A. ., & Khunti, K. . (2022). Significant reduction in chronic kidney disease progression with sodium-glucose cotransporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes in a UK clinical setting. Diabetes Obes Metab. http://doi.org/10.1111/dom.14799